+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2018-01-10Number of Pages: 226

Anticancer Drugs Market (Drug Type - Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), and Hormonal Drugs; Therapy Type - Chemotherapy, Targeted Therapy, and Immunotherapy; Cancer Type - Lung Cancer, Breast Cancer, Leukemia, and Colorectal Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Anticancer Drugs Market: Snapshot

Cancer is one of the leading cause of death worldwide and considered as the second major cause of death after cardiovascular diseases. The drugs that are used to prevent or reduce the cell proliferation of cancer tissues are termed as anticancer drugs. These drugs are used for treatment of various forms of cancer as well as in combination with radiation therapy, surgery or chemotherapy. The global market for anticancer drugs was worth US$ 85,000 million in 2016, with targeted drugs dominating the global market.

The global anticancer drugs market is witnessing a significant growth and is expected to expand at substantial CAGR during the forecast period of 2017–2025. Factors such as the rising prevalence of cancer in many regions, rising awareness towards cancer diagnosis and treatment, introduction of novel pipeline drugs and therapies, rise in cancer awareness programs such as breast cancer screening are expected to have a positive impact on the growth of global anticancer drugs market during the forecast period.

global-anticancer-drugs-market.jpg

Drugs for Lung Cancer to Continue to See High Uptake

The global anticancer drugs market is segmented on the basis of drug type, therapy type and cancer types. Based on drug type, the global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs. Targeted drugs segment accounted for over 40% share in terms of value of the global anticancer drugs market in 2016. The segment is anticipated to dominate the global anticancer drugs market throughout the forecast period due to increase in uptake of targeted therapies, specific activity of the drugs, and limited side effects as compared to other types.

Based on the therapy type, the global anticancer drugs market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Targeted therapy is expected to be the leading segment and is expected to expand at 6%-7% CAGR over the forecast period due to shift of preference from chemotherapy to targeted therapy. Based on cancer types, the global market is segmented into lung cancer, breast cancer, leukemia, and colorectal cancer. The segment of lung cancer is expected to expand at a robust CAGR of over 6% during the forecast period due to high prevalence and incidence of lung cancer and promising pipeline for non-small cell lung cancer (NSCLC) drugs.

Developed Regions to Remain at the Fore of Development of Anticancer Drugs Market

Geographically, North America and Europe are the leading regional markets with promising revenue opportunity for the global market. The U.S, U.K and Germany show high adoption for anticancer drugs as compared other regions due to developed healthcare infrastructure, targeted efforts of government and NGOs towards cancer management, prevalence of unhealthy lifestyle, and high prevalence of the disease in the regions.

The market for anticancer drugs Asia Pacific is expected to show expansion at a rapid pace during the forecast period. Developed countries such as Australia and Japan are favorable for the growth of the market. Projected pipeline drugs, rising prevalence of number of forms of cancer, rising disposable incomes, and increased awareness regarding the benefits of early diagnosis are driving the growth of the regional market. India and China are attractive markets due high prevalence of the disease and entry of established market players. The market in regions such as Latin America and Middle East and Africa is expected to grow at moderate rate during the forecast period.

Some of the key players in the global anticancer drugs market are F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.

Global Anticancer drugs Market: Scope and Research Methodology

This report on the global anticancer drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global anticancer drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global anticancer drugs market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of features of different type of drugs, therapies and cancer types. Additionally, market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Anticancer drugs Market: Segmentation

Cancer is caused due to abnormal growth of the cells. Anticancer drugs are also known as antineoplastic drugs. These drugs prevents and inhibits the growth of cancer cells.

Based on drug types, global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs. The targeted drugs segment is further segmented into monoclonal antibodies, tyrosine kinase inhibitors and others. The segment is anticipated to hold a significant share of the global market. The targeted drugs have a significant demand and is expected to continue dominating the global market throughout the forecast period.

Based on therapy type, global anticancer drugs market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period. Side effects of chemotherapy and specificity of the targeted drug are the factors driving the growth of global market.

Based on cancer types, the global anticancer drugs market is segmented into lung cancer, breast cancer, leukemia, colorectal cancer and others. The lung cancer segment is expected to expand at the fast rate due to high prevalence of the disease worldwide.

Anticancer drugs Market: Geographical and Competitive Dynamics

Geographically, the global anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.

The global anticancer drugs market has been segmented as follows:

Global Anticancer drugs Market, by Drug Type

  • Cytotoxic Drugs
    • Alkylating Agents
    • Antimetabolites
    • Others
  • Targeted Drugs
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitors
    • Others
  • Hormonal Drugs

Global Anticancer drugs Market, by Therapy Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

Global Anticancer drugs Market, by Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Leukemia
  • Colorectal Cancer
  • Others

Global Anticancer Drugs Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & NZ
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of MEA


 
 
Back To Top